El interés en corto de Kezar Life Sciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Kezar Life Sciences. Los datos de interés en corto se actualizan cada dos semanas.

Kezar Life Sciences (NASDAQ:KZR) Bolsa, Informe de interés en corto

KEZAR LIFE SCIENCES INC

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

WIIM

AMPX

Amprius Technologies shares are trading higher after the company reported better-than-expected Q1 financial results.

Koppers Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.62 by 14.52 percent. This is a 14.52 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $456.50 million which missed the analyst consensus estimate of $490.57 million by 6.94 percent. This is a 8.26 percent decrease over sales of $497.60 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Koppers Hldgs Q1 Adj. EPS $0.71 Beats $0.62 Estimate, Sales $456.50M Miss $490.57M Estimate

&nbsp;
80% Tariff on China seems right! Up to Scott B.
&nbsp;
&nbsp;

Macro Economic Events

Global

Economics

President Trump On Truth Social: '80% Tariff on China seems right! Up to Scott B.'

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) with a Buy and lowers the price target from $15 to $12.

Price Target

Analyst Ratings

FEMY

HC Wainwright & Co. Maintains Buy on Femasys, Lowers Price Target to $12

Federal Reserve

Fed's Kugler Says Q1 Growth Data Showed Front Loading Ahead Of Tariffs, Near Term There Could Be A Slow Down In Economy

Illumin Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ILLM#TSX">ILLM</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 100 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $29.08 million which beat the analyst consensus estimate of $19.59 million by 48.45 percent. This is a 16.55 percent increase over sales of $24.95 million the same period last year.

TSX:ILLM

Illumin Holdings Q1 EPS $(0.04) Misses $(0.02) Estimate, Sales $29.08M Beat $19.59M Estimate

FOXF

Fox Factory Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.84 by 4.76 percent. This is a 528.57 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $1.93 billion which beat the analyst consensus estimate of $1.84 billion by 4.73 percent. This is a 69.33 percent increase over sales of $1.14 billion the same period last year.

Anglogold Ashanti Q1 Adj. EPS $0.88 Beats $0.84 Estimate, Sales $1.93B Beat $1.84B Estimate

HROW

Harrow shares are trading lower after the company reported worse-than-expected Q1 financial results.

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), the world&#8217;s second-largest cryptocurrency by market capitalization, has soared 20% within 24 hours following the successful deployment of its <a href="https://www.benzinga.com/content/45294226/ethereum-price-surges-after-pectra-upgrade-bulls-now-eye-10-000-target">Pectra upgrade on May 7</a>.
What Happened: This surge, the largest single-day gain for ETH in four years, has reignited optimism among investors and developers, positioning Ethereum for a potential price breakout.
The Pectra upgrade, described as the most significant overhaul since the 2022 Merge, introduces a suite of improvements aimed at enhancing scalability, user experience and staking efficiency.
As the crypto community buzzes with excitement, analysts are dissecting whether this milestone could propel ETH past the $2,000 mark for the first time since March 2025.
Speaking with Benzinga, Peter Chung of Presto Labs said despite the price move, as the macro worries continue to subside on the back of the positive tariff-related headlines, investors are willing to move further up on the risk curve to higher beta asset beyond Bitcoin, especially given alts huge underperformance so far.
Moreover, he added that the series of announcement last night on tokenization, like Robinhood&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) putting U.S. stocks on blockchain, Supperstate launching &#8216;Open Bell&#8217;, bode well for Ethereum, which is the most popular based layer for the tokenization.
The Pectra Upgrade: A Game-Changer For Ethereum
Activated on May 7, 2025, at 10:05 AM UTC, the Pectra upgrade represents Ethereum's 16th major network update since its inception in 2015. 
Combining the Prague execution layer and Electra consensus layer upgrades, Pectra integrates 11 Ethereum Improvement Proposals (EIPs), making it the largest hard fork in the blockchain's history. 
<a href="https://coinjournal.net/news/ethereum-eth-sees-major-uptick-as-pectra-upgrade-goes-live/">According</a> to Tim Beiko, who oversees Ethereum's core protocol meetings, Pectra is second only to the Merge in its transformative potential, redefining staking economics and validator efficiency across the ecosystem.
Among the standout features is EIP-7702, which introduces account abstraction, allowing externally owned accounts (EOAs) to function like smart contracts within a single transaction. 
This enables users to pay transaction fees with tokens other than ETH and enhances wallet functionality, making Ethereum more user-friendly. 
Ivo Georgiev, CEO of Ambire, a self-custodial smart wallet, <a href="https://cointelegraph.com/news/lockbit-ransomware-breach-bitcoin-addresses-leaked">called </a>EIP-7702 "the single greatest UX upgrade to Ethereum so far," noting that wallets like Ambire and Trust Wallet have already adopted these features.
Another key change is EIP-7251, which raises the staking limit for validators from 32 ETH to 2,048 ETH—a 64-fold increase. 
This adjustment streamlines staking operations for both individual and institutional validators, reducing operational complexity and encouraging greater participation in Ethereum's proof-of-stake system. 
Additionally, Pectra doubles the number of data "blobs" Ethereum can handle, building on the Dencun upgrade of March 2024 to keep transaction fees on Layer 2 (L2) blockchains affordable. 
These enhancements aim to bolster Ethereum's scalability, particularly for rollups, which are critical to the network's Layer 2 ecosystem.
Despite a rocky development journey, including failed testnet deployments on Holesky and Sepolia due to configuration issues, the successful Hoodi testnet in March 2025 paved the way for Pectra's mainnet launch. 
Ethereum Foundation researcher Justin Drake <a href="https://cryptoslate.com/post-pectra-ethereum-now-targets-efficiency-with-60-million-gas-limit-expansion/">confirmed</a> that validators are already configured for post-Pectra efficiency measures, such as a 60 million gas limit expansion to boost transaction throughput.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45138065/uae-sets-global-benchmark-for-crypto-banking-integration-amina-banks-rohan-misra-says">UAE Sets Global Benchmark For Crypto-Banking Integration, Amina Bank&#8217;s Rohan Misra Says</a>
Market Impact And Investor Sentiment
The market's response to Pectra was swift and decisive. ETH's price, which had been trading around $1,830 before the upgrade, surged to over $2,400 on Friday morning, recording the strongest single-day increase since 2021 on Thursday.
Trading volumes spiked by nearly 46%, driven by heightened activity in the Ethereum Virtual Machine (EVM), which Pectra has made faster, cheaper, and more scalable. 
The upgrade also triggered a surge in network activity, reducing ETH's circulating supply to an 18-day low of 120.69 million ETH, creating upward price pressure.
Analysts attribute the rally to renewed confidence in Ethereum's technical roadmap. 
Posts on microblogging site X echoed this sentiment, with users highlighting Pectra's potential to unlock mass adoption through faster transactions, lower gas fees, and improved scalability. 
However, some market watchers remain cautious, noting that ETH futures premiums remained flat at 3% post-upgrade, signaling a lack of aggressive bullish bets from leveraged traders. 
Additionally, Ethereum-based ETFs have <a href="https://sosovalue.com/assets/etf/us-eth-spot">seen</a> $16.11 million in net outflows since January 2025, reflecting institutional hesitation.
Ethereum's Upgrade Legacy
Pectra builds on a decade of Ethereum upgrades, each addressing critical limitations. 
The 2022 Merge transitioned Ethereum from energy-intensive proof-of-work to proof-of-stake, slashing its carbon footprint by 99.95%. 
The 2024 Dencun upgrade reduced Layer 2 transaction costs, making rollups more viable for decentralized applications (DApps). 
Since its launch, Ethereum has undergone approximately 20 major upgrades, with Pectra marking a continuation of its commitment to scalability, security, and decentralization.
However, Pectra's immediate impact on DApp interoperability remains limited. 
Unlike Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) or BNB Chain (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), Ethereum's Layer 2 ecosystem still faces challenges in seamless asset and data bridging, which may explain why ETH has struggled to reclaim its March 2025 high of $2,200. 
Analysts suggest that a surge in DApp and network activity could drive further price recovery, potentially pushing ETH toward $3,000 if bullish momentum persists.
What Lies Ahead
As Ethereum charts its path forward, Pectra sets the stage for future upgrades like Fusaka, which will further refine Layer 2 and Layer 3 scalability. 
The upgrade has already spurred staking activity, with 627,000 ETH staked since mid-February 2025, reversing a pre-Pectra decline. 
Companies like BTCS Inc. are leveraging Pectra to roll out initiatives like the Staker Protection Plan, aimed at improving transaction inclusion and regulatory compliance.
While Pectra's technical achievements are undeniable, its long-term impact hinges on market adoption and developer innovation. 
For now, Ethereum's 20% surge underscores the market's faith in its evolution as the leading smart contract platform. 
As one X user put it, "Pectra is where Ethereum starts feeling like a modern network". 
Whether this upgrade marks ETH's breakout moment remains to be seen, but for the first time in years, Ethereum is back in the spotlight.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45297511/98-of-pump-fun-tokens-are-frauds-the-extractive-nature-of-solana-meme-coins">98% Of Pump.fun Tokens Are Frauds: The Extractive Nature Of Solana Meme Coins</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$ETH

$SOL

HOOD

Ethereum Explodes 25% Higher To $2,400, Notches Largest 1-Day Gain In 4 Years

AMN Healthcare Services shares are trading higher after the company reported better-than-expected Q1 financial results.

Boston Pizza Royalties (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BPF#TSX">BPF</a>) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.39 by 46.15 percent. This is a 43.24 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $12.28 million which missed the analyst consensus estimate of $12.40 million by 0.95 percent. This is a 4.08 percent increase over sales of $11.80 million the same period last year.

TSX:BPF

Boston Pizza Royalties Q1 EPS $0.21 Misses $0.39 Estimate, Sales $12.28M Miss $12.40M Estimate

MITK

Mitek Systems shares are trading higher after the company reported better-than-expected Q2 financial results.

CTKB

Cytek Biosciences shares are trading lower after the company reported worse-than-expected Q1 EPS results and cut its FY25 sales guidance.

Citigroup analyst Paul Lejuez upgrades National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) from Neutral to Buy and raises the price target from $13 to $21.

Upgrades

Citigroup Upgrades National Vision Holdings to Buy, Raises Price Target to $21

Needham analyst Scott Berg maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Buy and lowers the price target from $100 to $75.

BILL

Needham Maintains Buy on BILL Holdings, Lowers Price Target to $75

GOGO

Gogo shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance above estimates.

ORGO

Organogenesis Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

IOVA

Iovance Biotherapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, HC Wainwright lowered its price target on the spot from $32 to $20.

DXYN

Dixie Gr Q1 EPS $(0.12) Up From $(0.16) YoY, Sales $62.99M Down From $65.25M YoY

Press Releases

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Comments

Kezar Life Sciences

Interés en corto

Kezar Life Sciences (NASDAQ:KZR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL